| First Author | Soehnlein O | Year | 2011 |
| Journal | Sci Transl Med | Volume | 3 |
| Issue | 103 | Pages | 103ra98 |
| PubMed ID | 21974936 | Mgi Jnum | J:178318 |
| Mgi Id | MGI:5298141 | Doi | 10.1126/scitranslmed.3002531 |
| Citation | Soehnlein O, et al. (2011) Neutrophil-derived cathelicidin protects from neointimal hyperplasia. Sci Transl Med 3(103):103ra98 |
| abstractText | Percutaneous transluminal angioplasty with stent implantation is used to dilate arteries narrowed by atherosclerotic plaques and to revascularize coronary arteries occluded by atherothrombosis in myocardial infarction. Commonly applied drug-eluting stents release antiproliferative or anti-inflammatory agents to reduce the incidence of in-stent stenosis. However, these stents may still lead to in-stent stenosis; they also show increased rates of late stent thrombosis, an obstacle to optimal revascularization possibly related to endothelial recovery. Here, we examined the contribution of neutrophils and neutrophilic granule proteins to arterial healing after injury. We found that neutrophil-borne cathelicidin (mouse CRAMP, human LL-37) promoted reendothelization and thereby limited neointima formation after stent implantation. We then translated these findings to an animal model using a neutrophil-instructing, biofunctionalized, miniaturized Nitinol stent coated with LL-37. This stent reduced in-stent stenosis in a mouse model of atherosclerosis, suggesting that LL-37 may promote vascular healing after interventional therapy. |
